|Dr. Martine A. Rothblatt||Founder, Chairman & CEO||2.23M||16.5M||1955|
|Mr. Michael I. Benkowitz||Pres & COO||1.27M||N/A||1972|
|Mr. James C. Edgemond||CFO & Treasurer||972.46k||N/A||1968|
|Mr. Paul A. Mahon||Exec. VP, Gen. Counsel & Corp. Sec.||1.38M||N/A||1964|
|Kevin Gray||Sr. VP of Strategic Operations & Logistics||N/A||N/A||N/A|
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops implantable system for Remodulin; and the RemUnity system for delivery of intravenous and subcutaneous Remodulin; esuberaprost, RemoPro, and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
United Therapeutics Corporation’s ISS Governance QualityScore as of April 1, 2018 is 4. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 6; Compensation: 2.